Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $80.0 million.

  • Mimedx's Total Liabilities rose 2728.72% to $80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.0 million, marking a year-over-year increase of 2728.72%. This contributed to the annual value of $70.8 million for FY2024, which is 2649.43% down from last year.
  • Latest data reveals that Mimedx reported Total Liabilities of $80.0 million as of Q3 2025, which was up 2728.72% from $74.5 million recorded in Q2 2025.
  • Mimedx's 5-year Total Liabilities high stood at $106.8 million for Q1 2021, and its period low was $62.1 million during Q2 2024.
  • Its 5-year average for Total Liabilities is $86.3 million, with a median of $93.6 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 3563.65% in 2024, then soared by 2728.72% in 2025.
  • Mimedx's Total Liabilities (Quarter) stood at $95.4 million in 2021, then rose by 1.65% to $96.9 million in 2022, then decreased by 0.61% to $96.3 million in 2023, then dropped by 26.49% to $70.8 million in 2024, then increased by 13.04% to $80.0 million in 2025.
  • Its Total Liabilities was $80.0 million in Q3 2025, compared to $74.5 million in Q2 2025 and $67.6 million in Q1 2025.